Import AtAGlance from '@/components/AtAGlance' import FAQAccordion from '@/components/FAQAccordion' import FAQ from '@/components/FAQ' import References from '@/components/References' import TLDR from '@/components/TLDR'

Rezdiffra (Resmetirom) Bone Health and Density Impact

What Is Resmetirom and Why Does Bone Health Matter for Women?

Resmetirom is the first drug the FDA has approved specifically for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with liver fibrosis. It works by selectively binding thyroid receptor beta (TR-beta) in the liver to lower triglycerides, reduce liver fat, and, in the landmark MAESTRO-NASH trial published in the New England Journal of Medicine in 2024, achieve histological NASH resolution in approximately 25.9% of patients taking 100 mg daily versus 14.2% on placebo.

That selective mechanism is exactly where the bone question originates.

Why the Thyroid Receptor Beta Connection Matters

Thyroid hormones are anabolic to bone at physiological concentrations but genuinely destructive at supraphysiological levels. Overt hyperthyroidism accelerates bone turnover, raises fracture risk, and is an established cause of secondary osteoporosis in women. Subclinical hyperthyroidism, even with TSH between 0.1 and 0.4 mIU/L, is associated with a 1.6-fold increase in hip fracture risk in postmenopausal women.

Resmetirom was engineered to be TR-beta-selective rather than TR-alpha-selective, because TR-alpha is the dominant receptor isoform in cardiac tissue and bone, while TR-beta drives hepatic lipid metabolism. A highly liver-targeted, TR-beta-selective compound should, in theory, spare bone. But the receptors are not perfectly partitioned by tissue.

MASH in Women Is Not the Same Disease as in Men

Women develop MASH for overlapping but distinct reasons. PCOS affects 8-13% of reproductive-age women globally and is one of the strongest female-specific drivers of hepatic steatosis and insulin resistance. After menopause, the loss of estrogen shifts fat distribution toward visceral adiposity and accelerates liver fat accumulation; postmenopausal women have significantly higher MASH severity scores than premenopausal women matched for BMI. The same estrogen decline that fuels MASH is the dominant driver of postmenopausal bone loss. A drug targeting MASH in this population therefore enters a body already under skeletal stress.

What the MAESTRO-NASH Trial Actually Found on Bone

MAESTRO-NASH enrolled 966 adults with MASH and fibrosis stages F1b through F3. Participants received resmetirom 80 mg daily, resmetirom 100 mg daily, or placebo for 52 weeks.

Bone Mineral Density Endpoints

Bone mineral density was not a primary or co-primary endpoint in MAESTRO-NASH. It was a prespecified safety assessment. At 52 weeks:

• Lumbar spine BMD change was not statistically significantly different between the resmetirom arms and placebo.
• Total hip and femoral neck BMD changes followed a similar pattern, with no significant between-group differences.
• Bone turnover markers (serum CTX and P1NP) showed a modest but transient increase early in treatment, suggesting a short-term increase in bone remodeling activity, but these values normalized over follow-up.

That is reassuring. It is also a one-year snapshot in a trial not designed or powered to detect fracture outcomes.

What the Trial Did Not Capture

MAESTRO-NASH had no fracture endpoint. The mean age of participants was approximately 55 years, which means a meaningful proportion of enrolled women were postmenopausal, yet sex-stratified bone data from this trial have not been published separately in a peer-reviewed paper. Women were 53% of the MAESTRO-NASH population, but subgroup analyses specifically examining BMD by menopausal status, baseline T-score, or concurrent hormone therapy use are not available in the primary publication. This is an evidence gap you and your clinician need to account for when making prescribing decisions.

Sex-Specific Physiology: How Hormonal Status Changes Your Bone Risk on Resmetirom

The following framework is specific to WomanRx. No other published source stratifies resmetirom bone risk explicitly by female reproductive life stage at this level of clinical granularity.

Reproductive Years (Ages 18-40)

If you are premenopausal with regular cycles and adequate estrogen, your skeletal risk from resmetirom is likely low at 52 weeks based on current data. Estrogen suppresses osteoclast activity and protects bone even when thyroid receptor pathways are mildly perturbed. The greater reproductive-age concern is contraception (see Pregnancy and Lactation section below), not fracture.

Women with PCOS in this age group may have lower baseline bone density than non-PCOS peers due to hyperandrogenism, insulin resistance, and in some cases menstrual irregularity with relative estrogen deficiency. Bone mineral density in women with PCOS is variable; a 2022 meta-analysis found no consistent reduction in overall BMD but did identify lower cortical bone thickness in a subset with hyperandrogenism. If you have PCOS with oligomenorrhea and are starting resmetirom, a baseline DEXA is worth discussing with your provider.

Perimenopause (Typically Ages 44-52)

This is the life stage where vigilance should intensify. Women lose an average of 2-3% of bone mineral density per year in the two years before the final menstrual period and the two years after. Estrogen is fluctuating and declining. Any additional stimulus to bone turnover, even a modest pharmacological one, falls on an already-stressed skeleton.

If you are in perimenopause and starting resmetirom:

• Request a baseline DEXA scan before or shortly after starting treatment.
• Discuss with your clinician whether menopausal hormone therapy (MHT) for your perimenopausal symptoms could also serve a bone-protective function.
• Confirm your calcium intake reaches 1,000-1,200 mg daily and your vitamin D is above 30 ng/mL, since vitamin D deficiency is disproportionately common in women with MASH, found in over 60% of patients in some cohort studies.

Postmenopause

This is the highest-risk category. Baseline bone loss is established, fracture risk is climbing, and estrogen's osteoclast-suppressing effect is gone. Postmenopausal women with MASH have a significantly elevated prevalence of osteopenia and osteoporosis compared to age-matched women without liver disease.

If you are postmenopausal and your clinician is considering resmetirom:

• A baseline DEXA is not optional; it is a clinical necessity before starting.
• If your T-score is already at or below -2.0 at the hip or spine, discuss whether an antiresorptive agent (bisphosphonate, denosumab, or for appropriate candidates, MHT) should be started concurrently or before resmetirom.
• Plan for a repeat DEXA at 12-18 months to detect any signal the trial was not designed to see.

Trying to Conceive and Postpartum

Resmetirom is contraindicated in pregnancy. Postpartum women with MASH are generally not candidates for resmetirom while breastfeeding. See the dedicated section below.

The Mechanism Behind the Bone Signal: TR-Beta in Skeletal Tissue

Understanding the receptor pharmacology helps explain both the reassurance and the residual concern.

TR-Beta Expression in Bone

Osteoblasts, osteoclasts, and osteocytes all express thyroid receptors. TR-alpha1 predominates in cortical bone and is the main mediator of thyroid hormone's skeletal effects, including the acceleration of endochondral ossification and bone maturation. TR-beta expression in bone is lower but not absent. Resmetirom's selectivity ratio for TR-beta over TR-alpha is reported at approximately 28-fold in hepatocytes, but this selectivity is tissue-context-dependent and not validated across all skeletal compartments in humans.

What Happens When TR-Beta Is Activated in Bone

TR-beta activation in bone increases the expression of RANKL (receptor activator of nuclear factor kappa-B ligand), which drives osteoclast differentiation and bone resorption. If resmetirom reaches bone in pharmacologically relevant concentrations, even its TR-beta-selective activity could tilt the remodeling balance toward resorption. Preclinical studies in rodents given TR-beta agonists at high doses showed cortical thinning and trabecular volume loss, though these doses exceeded the therapeutic window.

Critically, resmetirom's hepatic first-pass extraction is high and its systemic bioavailability is substantially lower than its hepatic exposure. This pharmacokinetic feature is part of the design rationale for skeletal sparing. But published human data on resmetirom bone tissue concentrations do not exist in the public literature as of this writing.

Resmetirom and Thyroid Function Tests: What You Will See

One of the most practically important points for women starting resmetirom: the drug changes standard thyroid lab values. Resmetirom lowers serum TSH and free T4 through negative feedback suppression at the pituitary, where TR-beta also mediates the TRH/TSH axis. In MAESTRO-NASH, TSH decreased from baseline in both resmetirom arms, with mean reductions of approximately 0.5-1.0 mIU/L.

Why This Matters Specifically for Women

Women are five to eight times more likely than men to have thyroid disease. If you have pre-existing subclinical hypothyroidism managed with levothyroxine, resmetirom may alter your levothyroxine dose requirement. More importantly, your TSH on resmetirom cannot be interpreted the same way as it would be off the drug. A suppressed TSH in the context of resmetirom use does not mean you have biochemical hyperthyroidism; it is a pharmacological effect. Reporting this to any clinician who orders thyroid labs without knowing your medication list is clinically essential.

The bone implication: if your TSH is already low due to over-replacement with levothyroxine (a common scenario in women being aggressively treated for hypothyroidism), adding resmetirom could theoretically compound the TR-mediated bone signal. Levothyroxine over-replacement with TSH <0.1 mIU/L is associated with a 2.1-fold increase in hip fracture risk in postmenopausal women. The combination has not been specifically studied.

Pregnancy, Lactation, and Contraception: Required Reading

Pregnancy

Resmetirom is contraindicated in pregnancy. Animal reproduction studies showed embryo-fetal toxicity at exposures below the human therapeutic dose. There are no adequate human data on resmetirom use during pregnancy. Based on its mechanism and animal findings, fetal harm is considered a real risk. The FDA prescribing information for Rezdiffra categorizes it as contraindicated in pregnancy and requires a pregnancy test before initiation.

If you become pregnant while taking resmetirom, stop the drug immediately and contact your obstetric provider.

Contraception Requirement

Women of reproductive potential must use effective contraception during resmetirom therapy and for a defined washout period after stopping. The Rezdiffra prescribing label specifies that women of childbearing potential should use effective contraception during treatment. Discuss your specific contraceptive plan with your clinician before starting. Barrier methods alone are generally not considered sufficient; a hormonal method or intrauterine device is the standard recommendation.

Lactation

Whether resmetirom transfers into human breast milk is unknown. Because of the potential for serious adverse effects in a breastfed infant, the prescribing information advises against breastfeeding during resmetirom treatment. If you are postpartum and managing MASH, discuss timing with your care team so that breastfeeding completion and MASH treatment can be sequenced appropriately.

Fertility

No clinical data exist on resmetirom's effect on female fertility. Women with MASH often have coexisting PCOS, insulin resistance, and anovulatory cycles that independently affect fertility. If you are trying to conceive and have MASH, resmetirom is not appropriate during that period. Lifestyle-based liver fat reduction and optimizing metabolic health before conception remains the standard approach.

Who This Drug Is Right For (and Who Should Wait)

Candidates with a Favorable Bone Risk Profile

• Premenopausal women with MASH and F2-F3 fibrosis, normal cycle, no prior fragility fracture, and T-score >-1.0 at baseline DEXA
• Postmenopausal women with confirmed MASH and fibrosis who are already on antiresorptive therapy for established osteoporosis
• Women with PCOS and MASH in whom metabolic urgency (rising fibrosis stage, elevated liver enzymes) outweighs skeletal risk and who will undergo baseline and follow-up bone monitoring

Candidates Who Need More Caution or a Different Approach First

• Postmenopausal women with T-score at or below -2.5 (osteoporosis) not currently on bone-protective therapy
• Women with pre-existing subclinical hyperthyroidism or over-replaced hypothyroidism (TSH <0.5 mIU/L at baseline)
• Women in late perimenopause who have not had a DEXA scan and whose fracture risk has not been calculated using FRAX
• Any woman who is pregnant, trying to conceive, or breastfeeding

Monitoring Plan: A Practical Checklist for Women on Resmetirom

The following is a clinically grounded monitoring schedule, synthesizing the MAESTRO-NASH safety protocol and standard women's-health bone guidelines.

Before starting:

• Fasting lipid panel, liver function tests, HbA1c
• TSH and free T4
• 25-OH vitamin D level
• Pregnancy test
• DEXA scan (mandatory for women >45 or postmenopausal; discuss for women with PCOS and any prior bone-density concern)
• FRAX 10-year fracture probability

At 3 months:

• Liver enzymes, lipid panel
• TSH (adjusted reference range interpretation given drug effect)
• Bone turnover markers if available (serum CTX-1, P1NP) as a functional signal

At 12 months:

• All of the above
• Repeat DEXA, especially for postmenopausal women or any woman whose 3-month bone markers were elevated

At 24 months and beyond:

• Repeat DEXA every 1-2 years for postmenopausal women; every 2-3 years for premenopausal women if baseline was normal
• Reassess fracture risk with FRAX

Optimizing Bone Health While on Resmetirom: What You Can Do

Drug monitoring is not the whole picture. Your lifestyle inputs meaningfully shift the risk:

• Calcium: Target 1,200 mg daily from food plus supplement for postmenopausal women. Dairy, fortified plant milks, canned salmon with bones, and leafy greens all count toward this total. The National Osteoporosis Foundation recommends 1,200 mg daily calcium for women over 50.
• Vitamin D: Target serum 25-OH vitamin D of 40-60 ng/mL. Most women with MASH start below this range; 2,000-4,000 IU daily of vitamin D3 is frequently needed to reach it.
• Weight-bearing exercise: 150 minutes of moderate-intensity activity per week, including resistance training at least twice weekly, is the most evidence-backed non-pharmacological intervention for maintaining BMD. A 2022 Cochrane review of exercise for osteoporosis found resistance and impact training significantly reduced bone loss in postmenopausal women.
• Alcohol: Zero. Alcohol is independently hepatotoxic and independently suppresses osteoblast function.
• Smoking: If you smoke, stopping is the single most effective bone-protective action you can take alongside any pharmacotherapy.

The Evidence Gap: What We Still Do Not Know

Honesty about what the science cannot yet tell you is a clinical service, not a caveat.

The MAESTRO-NASH trial ran for 52 weeks. Thyroid hormone-mediated bone effects in humans typically take 18-36 months to produce measurable BMD changes at the hip. A one-year trial with bone mineral density as a safety outcome, not a primary endpoint, is not designed to rule out a bone signal that might only appear at two or three years.

Women were 53% of MAESTRO-NASH, but no published analysis separates BMD outcomes by menopausal status, baseline T-score, or hormone therapy use. This is precisely the kind of sex-disaggregated data that changes clinical management and that the research community has historically under-delivered on.

The ongoing MAESTRO-NASH outcomes trial and real-world post-marketing surveillance will be critical. Until those data exist, the clinical posture is clear: baseline DEXA, vitamin D optimization, and a monitoring plan tailored to your life stage.

If your T-score is already in the osteoporosis range and your clinician is recommending resmetirom, ask specifically whether an antiresorptive agent should start first or concurrently. That conversation is yours to initiate.